Business
Patent Board Upholds Seer's Nano and Micro Particle Protein Enrichment Patent in a Challenge by Bruker Subsidiaries
23 claims of U.S. Patent No. 11,435,360 remain valid, supporting Seer's Proteograph® Product SuiteREDWOOD CITY, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leader in deep, unbiased proteomic insights, today announced that the Patent Trial and Appeal Board (“PTAB”) of the U.S. Patent and Trademark Office issued a Final Written Decision on March 23, 2026, in an inter partes review of U.S. Patent No. 11,435,360 B2 (the “’360 Patent”). The inter partes review was filed by
About this update from Seer, Inc.
[{"type":"image","alt":"Seer, Inc.","displaySize":"","headline":null,"caption":"Seer, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":95,"url":"https://media.zenfs.com/en/globenewswire.com/54cda3f3cc4c5a0012780bcda6451a0b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/KAzr34r.34V3qwddJvNZmA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMw--/https://media.zenfs.com/en/globenewswire.com/54cda3f3cc4c5a0012780bcda6451a0b","width":300,"height":95}},"lazy":false},{"type":"text","content":"23 claims of U.S. Patent No. 11,435,360 remain valid, supporting Seer's Proteograph® Product Suite","length":102,"tagName":"p"},{"type":"text","content":"REDWOOD CITY, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leader in deep, unbiased proteomic insights, today announced that the Patent Trial and Appeal Board (“PTAB”) of the U.S. Patent and Trademark Office issued a Final Written Decision on March 23, 2026, in an inter partes review of U.S. Patent No. 11,435,360 B2 (the “’360 Patent”). The inter partes review was filed by PreOmics GmbH and Biognosys AG, each a subsidiary of Bruker Corporation, challenging 11 of 29 claims of the ’360 Patent.","length":523,"tagName":"p"},{"type":"text","content":"The ’360 Patent covers methods for analyzing biological samples using engineered nano- and microparticles that form protein coronas, resulting in protein enrichment that underlies Seer’s Proteograph platform for deep proteomic analysis. The ’360 Patent is owned by The Brigham and Women’s Hospital, Inc. and is exclusively licensed to Seer.","length":340,"tagName":"p"},{"type":"text","content":"A total of 23 claims, including five challenged claims and 18 unchallenged claims, remain valid and protect Seer’s nanoparticle protein enrichment technology for analyzing biological samples, including cells, tissues and biofluids. The upheld claims are directed to detecting proteins across a wide concentration range and to particle-related aspects of Seer’s technology, both of which enable deep proteomic analysis.","length":418,"tagName":"p"},{"type":"text","content":"“The PTAB’s decision affirms the strength of our technology and our Proteograph platform,” said Omid Farokhzad, Chair and Chief Executive Officer of Seer. “Seer pioneered the Proteograph platform, and our approach enables the deep, reproducible, and scalable pr...